Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
533 hedge funds and large institutions have $25.4B invested in Alexion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 73 funds opening new positions, 224 increasing their positions, 176 reducing their positions, and 52 closing their positions.
40% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 52
27% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 176
14% more funds holding in top 10
Funds holding in top 10: 14 → 16 (+2)
3% more funds holding
Funds holding: 518 → 533 (+15)
16% less capital invested
Capital invested by funds: $30.2B → $25.4B (-$4.76B)
19% less call options, than puts
Call options by funds: $155M | Put options by funds: $192M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$284M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$191M |
| 3 |
O
OrbiMed
New York
|
+$158M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$108M |
| 5 |
ClearBridge Investments
New York
|
+$105M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.2B |
| 2 |
Royal London Asset Management
United Kingdom
|
-$1.07B |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$445M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$286M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$138M |
ALXN Hedge Fund Activity: Q2 2016 in Review
533 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2016, worth a combined $25.4B — down 16% from $30.2B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new ALXN positions and 52 closed out — a net gain of 21 holders — while 224 added to existing stakes and 176 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $284M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.2B.
- 533 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2016, up from 518 in Q1 2016.
- Funds reported $25.4B of Alexion Pharmaceuticals stock for Q2 2016, down 16% quarter-over-quarter.
- 73 funds opened new Alexion Pharmaceuticals positions in Q2 2016 and 52 closed out, a net change of +21 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2016 was Fidelity Investments, an estimated $284M added.
- The largest Alexion Pharmaceuticals seller in Q2 2016 was T. Rowe Price Associates, an estimated $1.2B sold.
Based on aggregated 13F filings for Q2 2016.